Risks of Incident Cardiovascular Disease With Concomitant Elevations in Lipoprotein(a) and LDL Cholesterol — The Framingham Heart Study

Two cholesterol-related risk factors that usually get measured separately may be most dangerous together. This Framingham analysis examined what happens when lipoprotein(a) and LDL cholesterol are both elevated in the same person.

Drawing on the long-running Framingham Offspring cohort with 15 years of follow-up, the investigators found that people carrying both high Lp(a) and moderately high LDL had the steepest cardiovascular risk — a 43 percent excess compared with those who had high LDL alone. The two factors did not simply add up; the combination flagged a distinctly higher-risk group.

The practical implication is a screening one. A patient with a borderline-looking LDL might be quietly reclassified into a high-risk category by a single Lp(a) measurement — the kind of inherited, rarely-tested risk that the most efficient diagnostic path is designed to surface. It argues for measuring Lp(a) in exactly the people whose conventional numbers look only mildly concerning.

We rate the evidence strong. It is a well-conducted analysis from one of the most trusted cohorts in cardiology, though as an observational study it shows association rather than proof that treating the combination changes outcomes.